Genus PLC Appointment of Chief Executive Officer Designate (0250V)
April 03 2023 - 2:00AM
UK Regulatory
TIDMGNS
RNS Number : 0250V
Genus PLC
03 April 2023
For Immediate Release 3 April 2023
Genus plc
('Genus', or the 'Company')
Appointment of Chief Executive Officer Designate
Genus plc (LSE: GNS), a leading global animal genetics company,
announces that Jorgen Kokke has been appointed by the Board as
Chief Executive Officer Designate with effect from 2 May 2023.
This follows the announcement made on 23 February 2023, that
Stephen Wilson will retire on 30 September 2023. Jorgen will become
Chief Executive Officer of Genus from 1 July 2023. From that date,
Stephen Wilson will step down from his role as Chief Executive
Officer, but will remain actively involved in the Company to
support the smooth transition of responsibility. Stephen will
deliver the full year results in September and continue in his role
as an executive director until his retirement on 30 September
2023.
Jorgen has deep experience in the international food and
agriculture sectors having spent the last 14 years in global
business leadership roles of increasing responsibility at Ingredion
Incorporated, a leading food and beverage i ngredient solutions
company, listed on the New York Stock Exchange. Most recently,
Jorgen was Executive Vice President & President Americas with
responsibility for all operational and strategic management
decisions across its $6 billion North and South American
businesses, driving growth by leveraging research and development
led innovation and commercial and operational excellence. Prior to
his time at Ingredion, Jorgen worked at CSM NV, another global
ingredients company, where he was Vice President of Food and
Nutrition and prior to that, at Unilever.
Iain Ferguson, Chairman of Genus, commented on Jorgen's
appointment:
"I am delighted to welcome Jorgen to Genus. He is an
internationally experienced business leader with extensive food
sector knowledge. Jorgen has proven international leadership, clear
strategic vision, and the ability to engage and continue to
motivate our employees and porcine and bovine customers. He is
ideally suited to lead Genus through the next stage of our
continued growth, and it is clear that Genus will continue to be in
strong hands. The Board and I would like to thank Stephen for his
ongoing commitment to the Company and his significant contributions
to its success."
Jorgen Kokke, designate Chief Executive Officer, responded:
"I am joining Genus because I can see the great potential for
the Company, which is already a global leader in the porcine and
bovine genetics market. I have been consistently impressed by the
quality of the people I've met within the business and the strength
of its culture. I'm excited by Genus's innovation, which includes
its PRRSv resistant pig programme, its global commercial reach and
its world leading product line-up. I believe Genus has an exciting
future and I will aim to drive forward its many strategic and
growth opportunities, delivering value to our customers, employees
and shareholders. I am also looking forward to working with Stephen
Wilson on a seamless transition and thank him for his continued
input."
Genus Tel: +44(0)1256
345970
Iain Ferguson, Chair
Alison Henriksen, Chief Financial
Officer
Buchanan Tel: +44(0)207
466 5000
Charles Ryland / Chris Lane
/ Verity Parker
This announcement is available on the Genus website
www.genusplc.com
About Genus
Genus is a world-leading animal genetics company. Genus creates
advances to animal breeding and genetic improvement by applying
biotechnology and sells added value products for livestock farming
and food producers. Its technology is applicable across livestock
species and is currently commercialised by Genus in the dairy, beef
and pork food production sectors.
Genus's worldwide sales are made in over seventy-five countries
under the trademarks 'ABS' (dairy and beef cattle) and 'PIC' (pigs)
and comprise semen, embryos and breeding animals with superior
genetics to those animals currently in farms. Genus's customers'
animals produce offspring with greater production efficiency, and
quality, and use these to supply the global dairy and meat supply
chains.
The Group's competitive edge has been created from the ownership
and control of proprietary lines of breeding animals, the
biotechnology used to improve them and its global supply chain,
technical service and sales and distribution network.
With headquarters in Basingstoke, United Kingdom, Genus
companies operate in over twenty-five countries on six continents,
with research laboratories located in Madison, Wisconsin, USA.
Regulatory Notes
Details of any payments to be made to Jorgen Kokke will be
disclosed in full in the Company's 2023 Directors' Remuneration
Report. Any such terms will be consistent with the Company's
approved Directors' Remuneration Policy.
This announcement is made in accordance with Listing Rule
9.6.11R. There are no matters to be disclosed in connection with
Listing Rule 9.6.13R (2) - (6).
This announcement contains inside information for the purposes
of article 7 of the Market Abuse Regulation (EU) 596/2014 as it
forms part of UK domestic law by virtue of the European Union
(Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with
the Company's obligations under Article 17 of MAR. The person
responsible for making this announcement on behalf of the Group is
Dan Hartley (General Counsel and Company Secretary).
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCSDLFMFEDSEDD
(END) Dow Jones Newswires
April 03, 2023 02:00 ET (06:00 GMT)
Genus (LSE:GNS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Genus (LSE:GNS)
Historical Stock Chart
From Jul 2023 to Jul 2024